Also known as: clinical depression
Major depressive disorder is a mood disorder marked by persistent depressive symptoms and clinically significant functional impairment. It is among the most common mental disorders and contributes substantial disability burden.
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Kintsugi, a startup developing AI to detect depression and anxiety from voice, is shutting down and open-sourcing its technology due to costly FDA regulatory hurdles. The company’s models analyzed brief speech samples and showed significantly higher depression detection rates than standard questionnaires in a health payer trial. The release aims to empower global research into voice biomarkers for mental healthcare.
Helus completed Phase 3 enrollment for HLP003 in depression; data due Q4 2026. Compass is on track for COMP360's NDA, and an ayahuasca ingredient showed promise in a phase 2a trial.
MRI-guided brain stimulation achieved 80% response rates for treatment-resistant depression versus 60% with conventional targeting, per a JAMA Psychiatry study. Separately, Barcelona researchers developed an MRI tool to accurately identify rare neurodegenerative tauopathies PSP and CBD, while experts in Paris discussed AI's growing role in predictive psychiatry.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07783906 |
Precision Closed-loop Brain-Computer Interface Neuromodulation for Treatment-Resistant Depression |
NOT_YET_RECRUITING | NA |
| NCT07775586 |
Home-Based Wearable rTMS Therapy for Moderate to Severe Depression |
NOT_YET_RECRUITING | NA |
| NCT07772531 |
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder |
NOT_YET_RECRUITING | PHASE2 |
| NCT07768397 |
Accelerated Versus Standard Intermittent Theta Burst Stimulation for Major Depressive Disorder |
NOT_YET_RECRUITING | NA |
| NCT07703722 |
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder |
RECRUITING | PHASE3 |
| NCT07633080 |
Magnesium Bisglycinate in Major Depressive Disorder |
RECRUITING | NA |
| NCT07611487 |
Multimodal MRI Study of Acupuncture's Rapid Antidepressant Mechanisms and Response Prediction in Depression |
NOT_YET_RECRUITING | NA |
| NCT07596914 |
Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study |
NOT_YET_RECRUITING | NA |
| NCT07594483 |
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium |
NOT_YET_RECRUITING | NA |
| NCT07592689 |
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) |
RECRUITING | PHASE3 |
